Holen Sie sich die Stockscreener-App
67.97
2.34%
1.50
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Will Arrowhead Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Trade Ideas & AI Forecast Swing Trade Picks - DonanımHaber
Behavioral Patterns of ARWR and Institutional Flows - news.stocktradersdaily.com
Trading Action: Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsGap Down & Detailed Earnings Play Strategies - moha.gov.vn
Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Movers & AI Powered Trade Plan Recommendations - Улправда
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $100.00 Price Target at Piper Sandler - MarketBeat
Piper Sandler Raises Arrowhead Pharma (ARWR) Price Target to $100 | ARWR Stock News - GuruFocus
Piper Sandler raises Arrowhead Pharma stock price target to $100 on Redemplo launch - Investing.com UK
ARWR (Arrowhead Pharmaceuticals) 12-1 Month Momentum % : 84.44% (As of Dec. 17, 2025) - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 54,298 Shares - MarketBeat
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 130,000 Shares of Stock - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching - ts2.tech
Arrowhead (ARWR) Experiences Notable Decline in Share Price - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 7.6%What's Next? - MarketBeat
Arrowhead (ARWR) Sees Significant Decline as Stock Drops Over 12% - GuruFocus
Hudson Bay Capital Management LP Purchases 46,870 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
36,469 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Marex Group plc - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approval, Plozasiran Breakthrough Status and ARO-MAPT Trial Progress - Sahm
WINTON GROUP Ltd Invests $660,000 in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
RBC Capital Maintains Arrowhead Pharmaceuticals (ARWR) Outperform Recommendation - Nasdaq
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 7th Annual CNS Delivery SummitSlideshow - Seeking Alpha
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025 - ts2.tech
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Arrowhead Pharma (ARWR) Receives Raised Price Target from RBC Ca - GuruFocus
Arrowhead Pharmaceuticals stock hits 52-week high at 71.62 USD By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals stock hits 52-week high at 71.62 USD - Investing.com
Arrowhead Pharma stock price target raised to $80 from $52 at RBC Capital - Investing.com Canada
RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk - marketscreener.com
Arrowhead Pharmaceuticals (ARWR) Valuation Check as ARO-MAPT Enters First Human Trial in Alzheimer’s Treatment - Yahoo Finance
History Review: Can Arrowhead Pharmaceuticals Inc stock surprise with earnings upsideJuly 2025 Closing Moves & Verified Momentum Stock Watchlist - moha.gov.vn
Michael Perry Sells 16,250 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock - MarketBeat
B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq
ARWR: B of A Securities Raises Price Target Amid Maintained Buy Rating | ARWR Stock News - GuruFocus
Bank of America Issues Positive Forecast for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap DownTime to Sell? - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial - ts2.tech
Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval - MSN
Arrowhead Pharmaceuticals Flourishes with Key Milestones and Growth Projections - StocksToTrade
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins - ts2.tech
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial - Investing.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year HighTime to Buy? - MarketBeat
Arrowhead Hits the Mark - Los Angeles Business Journal
Arrowhead’s Plozasiran Garners FDA Breakthrough Recognition - timothysykes.com
Arrowhead (ARWR) Begins Trials for Alzheimer's Treatment - GuruFocus
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Business Wire
Marshall Wace LLP Grows Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Norges Bank Invests $30.41 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
(ARWR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Edgestream Partners L.P. Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 5%What's Next? - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Price Target Increased by 17.24% to 59.24 - Nasdaq
Franklin Resources Inc. Purchases Shares of 81,226 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Therapy Designation for Plozasiran - Sahm
How Arrowhead Pharmaceuticals Inc. (HDP1) stock reacts to Fed tighteningEarnings Recap Summary & Risk Managed Investment Entry Signals - Newser
How analysts revise price targets for Arrowhead Pharmaceuticals Inc. (HDP1) stockPortfolio Value Report & Reliable Price Breakout Alerts - Newser
Fisher Asset Management LLC Has $7.14 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
What dividend safety rating applies to Arrowhead Pharmaceuticals Inc. (HDP1) stockWeekly Loss Report & Long-Term Capital Growth Strategies - Newser
Is Arrowhead Pharmaceuticals Inc. (HDP1) stock cheap vs fundamentalsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Breakthrough Approved: FDA approves pioneering FCS drug by Pasadena company - Pasadena Weekly
HC Wainwright Issues Pessimistic Estimate for ARWR Earnings - MarketBeat
What is HC Wainwright's Estimate for ARWR Q2 Earnings? - MarketBeat
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):